Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information



United Kingdom
St Dunstans House, High Street
Melrose, TD6 9RU


Vice Chairman
Company Secretary
Core Member
Core Member
Show All People


Tweed Renaissance Investors Capital

With investment deals valued at more than £3 million under its belt, Tweed Renaissance Investors Capital (TRI Cap) is one of Scotland’s newest business angel syndicates and also one of its most dynamic. For both investors and those seeking investment. TRI Cap is very firmly on the map. Since its launch in 2005 both membership and deals have maintained a keen pace, and they continue to actively seek both. Read their News pages to gain a snapshot of the organisation and the deals TRI Cap members have been involved in. In truth, TRI Cap is mature beyond its years, with many decades of first-rate entrepreneurial, financial and management experience round their board room table. Visit their Members page to learn a little more about their people.

Recent Milestones


Company Date Round Size Participants
4th aspect 8/2013Seed£400k3
MGB Biopharma 3/2010Venture Round$3.03M4
Syntropharma 12/2009Venture Round$640k3
Exterity 12/2008Venture Round£1.1M3
Factonomy 5/2008Series B$1.69M4
Powerphotonic 1/2008Venture Round$979k2
Syntropharma 11/2006Series A£1M3



  1. U.K. Web Marketing Firm, 4th Aspect, Tops Up Seed With £400K To Fund R&D & Sales Push ( [edit]
  2. Funding secured totalling almost £2M from angel syndicate ( [edit]
  3. Syntropharma Collects Follow-On Funding For Transdermal Patch ( [edit]
  4. Exterity raises £1.1m in funding ( [edit]
  5. Factonomy boosted by near£1m funding ( [edit]
  6. PowerPhotonic Ltd Secures Funding ( [edit]
  7. Syntropharma Secures Funding ( [edit]
Edit This Page
Last Edited 3/24/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy